Browsing Tag
iSCIB1+
2 posts
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.
Advanced melanoma immunotherapy enters a new phase as Scancell secures Phase 3 clearance
Scancell Holdings Plc, iSCIB1+, advanced melanoma, melanoma immunotherapy, FDA Phase 3 clearance, cancer vaccines, ImmunoBody platform